Weight loss medications drive consumer shifts and counterfeit drug risks

The rising use of GLP-1 based weight loss medications, commonly known as ‘weight loss pens’, is driving significant shifts in consumer behavior and presenting new public health risks.

A study by MindMiners involving over 2,000 people indicates that users are reorganizing their consumption habits to align with new health identities. Approximately one-third of users report better planning for supermarket shopping and restaurant choices. There is a noted increase in the consumption of mineral water, fruits, vegetables, and white meats, alongside a decrease in sugar and carbohydrate intake. This trend is expected to influence various sectors, including food and beverage, fashion, beauty, and fitness.

However, the surge in demand has led to a rise in counterfeit and irregular weight loss medications. The World Health Organization issued an alert in 2024 regarding falsified semaglutide batches globally. In Brazil, Anvisa has reinforced measures to combat irregularities in the importation, manipulation, and commercialization of these injectable drugs. Experts warn that purchasing these products through social media or informal intermediaries poses severe risks, including exposure to unknown substances, incorrect dosages, and lack of clinical supervision.